- Home
- AUUD vs ENVB Comparison
AUUD vs ENVB Comparison
Compare AUUD & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- ENVB
- Stock Information
- Founded
- AUUD 2012
- ENVB 1994
- Country
- AUUD United States
- ENVB United States
- Employees
- AUUD N/A
- ENVB N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- ENVB Health Care
- Exchange
- AUUD Nasdaq
- ENVB Nasdaq
- Market Cap
- AUUD 2.6M
- ENVB 2.7M
- IPO Year
- AUUD 2021
- ENVB N/A
- Fundamental
- Price
- AUUD $2.18
- ENVB $1.05
- Analyst Decision
- AUUD
- ENVB Strong Buy
- Analyst Count
- AUUD 0
- ENVB 1
- Target Price
- AUUD N/A
- ENVB $10.00
- AVG Volume (30 Days)
- AUUD 4.6M
- ENVB 310.9K
- Earning Date
- AUUD 08-08-2025
- ENVB 08-14-2025
- Dividend Yield
- AUUD N/A
- ENVB N/A
- EPS Growth
- AUUD N/A
- ENVB N/A
- EPS
- AUUD N/A
- ENVB N/A
- Revenue
- AUUD N/A
- ENVB N/A
- Revenue This Year
- AUUD N/A
- ENVB N/A
- Revenue Next Year
- AUUD N/A
- ENVB N/A
- P/E Ratio
- AUUD N/A
- ENVB N/A
- Revenue Growth
- AUUD N/A
- ENVB N/A
- 52 Week Low
- AUUD $2.12
- ENVB $1.01
- 52 Week High
- AUUD $26.86
- ENVB $8.40
- Technical
- Relative Strength Index (RSI)
- AUUD 34.79
- ENVB 39.65
- Support Level
- AUUD $2.12
- ENVB $1.10
- Resistance Level
- AUUD $2.64
- ENVB $1.47
- Average True Range (ATR)
- AUUD 0.24
- ENVB 0.10
- MACD
- AUUD 0.03
- ENVB -0.01
- Stochastic Oscillator
- AUUD 6.19
- ENVB 6.67
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.